CMF revisited in the 21st century

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 305-311

  Munzone, E ^a   Curigliano, G ^a   Burstein, H J ^b   Winer, E P ^b   Goldhirsch, A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant chemotherapy; Alkylating agents; Breast cancer; Classical CMF; Triple negative; Tumor heterogeneity

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PREDNISONE; TAMOXIFEN; VINCA ALKALOID; VINCRISTINE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; TRIPLE NEGATIVE BREAST CANCER;

EID: 84856332020     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr309     Document Type: Review

References (59)

1. Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405-410.
2. Canellos GP, De Vita VT, Gold GL et al. Cyclical combination chemotherapy for advanced breast carcinoma. Br \Med J 1974; 1: 218-220.
3. Moore MR, Jones SE, Bull JM et al. MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients. Cancer 1973; 32(1): 52-60.
4. Fisher B, Carbone P, Economou SG et al. 1-phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 1975; 292: 117-122.
5. Bonadonna G. Conceptual and practical advances in the management of breast cancer. J Clin Oncol 1989; 7(10): 1380-1397.
6. Fisher B, Redmond C, Dimitrov NV et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with nodenegative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989; 320: 473-478.
7. Mansour EG, Gray R, Shatila AH et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl JMed 1989; 320: 485-490.
8. Goldhirsch A, Colleoni M, Coates AS et al. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? Ann Oncol 1998; 9: 489-493.
9. Clahsen PC, Van de Velde CJH, Welvaart K. Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigators. J Clin Oncol 1995; 13: 33-41.
10. Tannock IF, Boyd NF, DeBoer G et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1399-1487.
11. Zambetti M, Valagussa P, Bonadonna G. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Updated results. Ann Oncol 1996; 7: 481-485.
12. Brandi M, De Nitrio A, Ditonno P et al. Oral versus intravenous CMF in metastatic breast cancer: a randomized trial. Int J Oncol 1994; 4: 559-565.
13. Engelsman E, Klijn JC, Rubens RD et al. 'Classical' CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III trial (10808). Eur J Cancer 1991; 27: 966-970.
14. O'Shaughnessy JA. Oral alkylating agents for breast cancer therapy. Drugs 1999; 58 (Suppl 3): 1-9.
15. Senn HJ, Jungi WF, Amgwerd R et al. Results of adjuvant LMF/BCG in N2 and N+ breast cancer. In Jones SE, Salmon SE (eds): Adjuvant Therapy of Cancer IV. Orlando, FL: Grune & Stratton 1984; 261-270.
16. Rivkin SE, Glucksberg H, Foulkes M. Adjuvant chemotherapy for operable breast cancer with positive axillary nodes. In Jones SE, Salmon SE (eds): Adjuvant Therapy of Cancer IV. Orlando, FL: Grune & Stratton 1984; 209-215.
17. Davis HL, Metter GE, Ramirez G et al. An adjuvant trial of L-phenylalanine mustard (L-PAM) vs cyclophosphamide (C), methotrexate (M), 5-fluorouracil (F) and vincristine (V)-CMFV following mastectomy for operable breast cancer. Proc Am Soc Clin Oncol 1981; 22: (Abstr 246).
18. Howell A, Rubens RD, Bush H et al. A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil in breast cancer. Recent Results Cancer Res 1984; 96: 74-79.
19. Bonadonna G,Moliterni A, ZambettiMet al. 30 years' followup of randomised studies of adjuvant CMF in operable breast cancer: cohort study.BMJ 2005; 330(7485): 217.
20. Misset JL, di Palma M, Delgado M et al. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil and vincristine versus cyclophosphamide, methotrexate and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol 1996; 14: 1136-1145.
21. Tancini G, Bonadonna G, Valagussa P et al. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1983; 1: 2-10.
22. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer: inadequacy of a single peri-operative cycle. N Engl J Med 1988; 319: 677-683.
23. Colleoni M, Litman HJ, Castiglione-Gertsch M et al. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomized trials investigating three versus six courses of CMF. Br J Cancer 2002; 86: 1705-1714.
24. Hrafnkesson J, Nilsson K, Soderberg M. Tolerance of radiotherapy combined with adjuvant chemotherapy in breast cancer. Acta Oncol 1987; 26: 269-272.
25. Fisher B, Brown AM,Dimitrov NV et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumours: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 1483-1496.
26. De Placido S, Perrone F, Carlomango C et al. CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer: a single centre randomised clinical trial (Naples GUN-3 study). Br J Cancer 1995; 71: 1283-1287.
27. Piccart M, Di Leo A, Beauduin M et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer. J Clin Oncol 2001; 19: 3103-3110.
28. Levine MN, Pritchard KI, Bramwell VH et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005; 23: 5166-5170.
29. Hutchins LF, Green SJ, Ravdin PM et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, nodenegative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 2005; 23(33): 8313-8321.
30. Fisher B, Anderson S, Tan-Chiu E et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001; 19(4): 931-942.
31. Ploner F, Jakesz R, Hausmaninger H et al. Randomized trial: one cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. Onkologie 2003; 26(2): 115-119.
32. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
33. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
34. Buzdar AU, Singletary SE, Valero V et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002; 8: 1073-1079.
35. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
36. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
37. Piccart MJ, Lohrisch C, Duchateau L et al. Taxanes in the adjuvant treatment of breast cancer: why not yet? J Natl Inst Monogr 2001; 30: 88-95.
38. Mamounas EP, Bryant J, Lembersky B et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23: 3686-3696.
39. Francis P, Crown J, Di Leo A et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 Randomized Trial. J Natl Cancer Inst 2008; 100: 121-133.
40. Gianni L, Baselga J, Eiermann W et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009; 27: 2474-2481.
41. Burnell M, Levine M, Chapman J. A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21). J Clin Oncol 2007; 25 (Suppl): (Abstr 550).
42. Ellis P, Barrett-Lee P, Bloomfield D et al. Preliminary results of the UK Taxotere as Adjuvant Chemotherapy (TACT) Trial. UK-CRUK trial. In 30th San Antonio Breast Cancer Symposium 2007 (Abstr 78). San Antonio, TX. 2007.
43. Poole CJ, Earl HM, Hiller L et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006; 355(18): 1851-1862.
44. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747-752.
45. Andre F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 2006; 3(11): 621-632 Review.
46. Fisher B, Dignam J, Mamounas EP et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptornegative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996; 14: 1982-1992.
47. Fisher B, Jeong J-H, Bryant J et al. Treatment of lymph-node-negative, estrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. Lancet 2004; 364: 858-868.
48. Rakha EA, El-Sayed ME, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
49. Lehmann-Che J, André F, Desmedt C et al. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist 2010; 15(3): 246-252.
50. O'malley FP, Chia S, Tu D et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009; 101: 644-650.
51. Gennari A, Sormani MP, Pronzato P et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008; 100: 14-20.
52. Falo C, Moreno A, Varela M et al. HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy. J Cancer Res Clin Oncol 2007; 133(7): 423-429.
53. Cheang M, Chia SK, Tu D et al. Anthracyclines in basal breast cancer: the NCICCTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 2009; 27 (Suppl): 15s (Abstr 519).
54. Tan DS, Marchió C, Jones RL et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008; 111: 27-44.
55. Colleoni M, Cole BF, Viale G et al. Classical CMF chemotherapy is more effective in selected breast cancer subtypes: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 2010; 28(18): 2966-2973.
56. Tassone P, Tagliaferri P, Perricelli A et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003; 88: 1285-1291.
57. Carey LA. Directed therapy of subtypes of triple-negative breast cancer. Oncologist 2010; 15 (Suppl 5): 49-56.
58. Bryant HE, Schultz N, Thomas H et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917.
59. O'Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364(3): 205-214.